- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01306396
Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight Children
February 28, 2011 updated by: University of Hohenheim
Investigation on the Preventive Effect of Reduced Fructose Consumption on the Development of Non-alcoholic Fatty Liver Disease in Children in a Long Term Study
The aim of the present study is to find out if a dietary intervention mainly focusing on fructose reduction has a preventive effect on the development and progression of NAFLD and the metabolic syndrome in overweight children.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
In the intervention study a total of 100 overweight and 50 normal weight children, aged 5-8 years have to be included.
At the beginning, two 24-h dietary recalls are performed to assess nutritional intake and fructose consumption.
Anthropometric parameters (body weight and height) are measured to calculate BMI and BMI-SDS of the children.
Physical activity during leisure time as well as socio-demographic status and "family background" are assessed using different questionnaires.
An ultrasound examination of the liver is performed in all participants for detection of signs of fatty liver.
From each child included in the study a fasting blood sample is taken to determine the following blood parameters: ALT, AST, γ-GT, uric acid, blood lipids (TG, HDL, LDL, Total cholesterol), blood alcohol, PAI-1 and endotoxin concentration.
A part of the blood sample is used for DNA-analysis.
In all children systolic (SBP) and diastolic (DBP) blood pressure are also measured.
An oral glucose tolerance test (OGTT) is performed after an overnight fast of 12 h (glucose concentration: 1.75 g/kg body weight, maximum 75g).
Simultaneously a glucose hydrogen breath test is performed to assess small intestinal bacterial overgrowth (SIBO).
After the check-ups at the beginning of the study, children are divided into two study groups: the intervention group and the control group.
Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%.
In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
If families participating in the control group wish, they receive a dietary counseling based on the references of the "DGE" at the beginning of the study.
After the first and the second study year the examinations are repeated in all participants (ultrasound examination only after the second study year).
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Baden-Württemberg
-
Stuttgart, Baden-Württemberg, Germany, 70599
- Recruiting
- University of Hohenheim, Dept. of Nutritional Medicine (180 a)
-
Contact:
- Ina Bergheim, Ph.D.
- Phone Number: ++49/711/4592-4102
- Email: ina.bergheim@uni-hohenheim.de
-
Principal Investigator:
- Ina Bergheim, Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 8 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI > 90 percentile for overweight children
- BMI < 90 percentile for normal weight children
- no signs of fatty liver (maximal fatty liver grade one or slightly elevated ALT, AST, γ-GT concentrations)
- children with metabolic disorders (prehypertension, high triglyceride, cholesterol or fasting glucose levels) are included with agreement of the pediatrics
Exclusion Criteria:
- liver disease (e.g. steatohepatitis)
- diabetes type 1 and 2
- renal insufficiency
- chronic disease of the gastrointestinal tract
- taking drugs affecting lipid or glucose metabolism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Intervention group
Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
|
Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%.
In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
|
|
No Intervention: Control group
Families participating in the control group are given only one dietary counseling based on the references of the "DGE" at the beginning of the study if they wish.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
prevalence of fatty liver disease
Time Frame: 2 years
|
Prevalence of fatty liver disease in ultrasound examination after 2 years
|
2 years
|
|
changes in blood lipid concentrations
Time Frame: 1, 2 years
|
changes in TG, HDL, LDL, total choelsterol concentrations in serum
|
1, 2 years
|
|
changes in blood pressure
Time Frame: 1, 2 years
|
changes in systolic (SBP) and diastolic (DBP) blood pressure
|
1, 2 years
|
|
changes in glucose metabolism
Time Frame: 1, 2 years
|
changes in oral glucose tolerance-test
|
1, 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in small intestinal bacterial overgrowth
Time Frame: 1, 2 years
|
changes in glucose hydrogen breath test
|
1, 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ina Bergheim, Ph.D., University of Hohenheim, Dept. of Nutritional Medicine (180 a)
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Engstler AJ, Aumiller T, Degen C, Durr M, Weiss E, Maier IB, Schattenberg JM, Jin CJ, Sellmann C, Bergheim I. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut. 2016 Sep;65(9):1564-71. doi: 10.1136/gutjnl-2014-308379. Epub 2015 May 25.
- Maier IB, Ozel Y, Wagnerberger S, Bischoff SC, Bergheim I. Dietary pattern and leisure time activity of overweight and normal weight children in Germany: sex-specific differences. Nutr J. 2013 Jan 15;12:14. doi: 10.1186/1475-2891-12-14.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Anticipated)
December 1, 2011
Study Completion (Anticipated)
December 1, 2012
Study Registration Dates
First Submitted
February 25, 2011
First Submitted That Met QC Criteria
February 28, 2011
First Posted (Estimate)
March 1, 2011
Study Record Updates
Last Update Posted (Estimate)
March 1, 2011
Last Update Submitted That Met QC Criteria
February 28, 2011
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 03105084 (IB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-alcoholic Fatty Liver Disease
-
Naga P. ChalasaniDSM Nutritional Products, Inc.CompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Non-Alcoholic Fatty LiverUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.WithdrawnFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
Hywel Dda Health BoardCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non Alcoholic Fatty Liver | Steatosis of LiverUnited Kingdom
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
Better TherapeuticsArizona Liver HealthCompletedNon-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty LiverUnited States
-
Badr UniversityNot yet recruitingNon-alcoholic Steatohepatitis NASH | Non-alcoholic Fatty Liver Disease NAFLDEgypt
-
University Hospital, ToulouseNot yet recruiting
-
Puerta de Hierro University HospitalHospital Universitario Marqués de ValdecillaNot yet recruitingNon-Alcoholic Fatty Liver Disease | Non Alcoholic SteatohepatitisSpain
Clinical Trials on dietary intervention mainly focusing on fructose reduction
-
Shijiazhuang Pingan HospitalCompletedAcute Myeloid LeukemiaChina
-
University of Southern DenmarkNovo Nordisk A/SCompleted
-
Campus Bio-Medico UniversityRecruiting
-
University of AlbertaCanadian Institutes of Health Research (CIHR); Alberta Health servicesRecruiting
-
Palo Alto Medical FoundationNational Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases | Asthma
-
National University of SingaporeRecruitingAllergic Rhinitis | Atopic Dermatitis | Allergic Diseases | AtopicSingapore
-
Riphah International UniversityCompleted
-
The University of Tennessee, KnoxvilleCompleted
-
UMC UtrechtTilburg University; VU University of Amsterdam; Ede Christian University of Applied...Recruiting
-
University of RwandaCompleted